{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:04:01Z","timestamp":1790435041066,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myeloid cells, especially mononuclear phagocytes, which include monocytes, macrophages and dendritic cells (DC), play vital roles in innate immunity, and in the initiation and maintenance of adaptive immunity. While T cell-associated activation pathways and cytokines have been identified and evaluated in inflammatory bowel disease (IBD) patients (Neurath, Nat Rev Gastroenterol Hepatol 14:269\u201378, 1989), the role of mononuclear phagocytes are less understood. Recent reports support the crucial role of DC subsets in the development of acute colitis models (Arimura et al., Mucosal Immunol 10:957\u201370, 2017), and suggest they may contribute to the pathogenesis of ulcerative colitis (UC) by inducing Th1\/Th2\/Th17 responses (Matsuno et al., Inflamm Bowel Dis 23:1524\u201334, 2017).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We performed in silico analysis and evaluated the enrichment of immune cells, with a focus on mononuclear phagocytes in IBD patient colonic biopsies. Samples were from different gut locations, with different levels of disease severity, and with treatment response to current therapies. We observe enrichment of monocytes, M1 macrophages, activated DCs (aDCs) and plasmacytoid dendritic cells (pDCs) in inflamed tissues from various gut locations. This enrichment correlates with disease severity. Additionally, the same mononuclear phagocytes subsets are among the top enriched cell types in both infliximab and vedolizumab treatment non-responder samples. We further investigated the enrichment of selected DC and monocyte subsets based on gene signatures derived from a DC- and monocyte-focused single cell RNA-seq (scRNA-seq) study (Villani et al., Science 356:eaah4573, 2017), and verified enrichment in both inflamed tissues and those with treatment resistance. Moreover, we validated an increased mononuclear phagocyte subset abundance in a Dextran Sulphate Sodium (DSS) induced colitis model in C57Bl\/6 mice representative of chronic inflammation.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We conducted an extensive analysis of immune cell populations in IBD patient colonic samples and identified enriched subsets of monocytes, macrophages and dendritic cells in inflamed tissues. Understanding how they interact with other immune cells and other cells in the colonic microenvironment such as epithelial and stromal cells will help us to delineate disease pathogenesis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12865-019-0322-z","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:03:04Z","timestamp":1573585384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-1308","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryasarathi","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lightcap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Faustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","volume":"14","author":"MF Neurath","year":"2017","unstructured":"Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24\u201330.","journal-title":"Autoimmun Rev"},{"key":"322_CR3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"issue":"5","key":"322_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"Heike Schmitt","year":"2018","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68:814\u201328.","journal-title":"Gut"},{"key":"322_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/apt.14550","volume":"47","author":"A Barr\u00e9","year":"2018","unstructured":"Barr\u00e9 A, Colombel J-F, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:896\u2013905.","journal-title":"Aliment Pharmacol Ther"},{"key":"322_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","volume":"17","author":"L Peyrin-Biroulet","year":"2019","unstructured":"Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, et al. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn\u2019s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:838\u2013846.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"322_CR7","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1097\/MIB.0000000000001204","volume":"23","author":"H Matsuno","year":"2017","unstructured":"Matsuno H, Kayama H, Nishimura J, Sekido Y, Osawa H, Barman S, et al. CD103+ dendritic cell function is altered in the colons of patients with ulcerative colitis. Inflamm Bowel Dis. 2017;23:1524\u201334.","journal-title":"Inflamm Bowel Dis"},{"key":"322_CR8","doi-asserted-by":"publisher","unstructured":"Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Crohn\u2019s Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus. 9. https:\/\/doi.org\/10.7759\/cureus.1177.","DOI":"10.7759\/cureus.1177"},{"key":"322_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00005-018-0519-5","volume":"66","author":"J Li","year":"2018","unstructured":"Li J, Glover SC. Innate lymphoid cells in inflammatory bowel disease. Arch Immunol Ther Exp. 2018;66:415\u201321.","journal-title":"Arch Immunol Ther Exp"},{"key":"322_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nri3087","volume":"11","author":"A Chow","year":"2011","unstructured":"Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. 2011;11:788\u201398.","journal-title":"Nat Rev Immunol."},{"key":"322_CR11","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1111\/j.1572-0241.2001.04686.x","volume":"96","author":"S Vuckovic","year":"2001","unstructured":"Vuckovic S, Florin T, Khalil D, Zhang M, Patel K, Hamilton I, et al. Cd40 and Cd86 Upregulation with divergent Cmrf44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol. 2001;96:2946\u201356.","journal-title":"Am J Gastroenterol"},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/gut.2004.040360","volume":"54","author":"DC Baumgart","year":"2005","unstructured":"Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut. 2005;54:228\u201336.","journal-title":"Gut"},{"key":"322_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.gastro.2005.05.013","volume":"129","author":"AL Hart","year":"2005","unstructured":"Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50\u201365.","journal-title":"Gastroenterology"},{"key":"322_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/gut.2004.063008","volume":"55","author":"P Middel","year":"2006","unstructured":"Middel P, Raddatz D, Gunawan B, Haller F, Radzun H-J. Increased number of mature dendritic cells in Crohn\u2019s disease: evidence for a chemokine mediated retention mechanism. Gut. 2006;55:220\u20137.","journal-title":"Gut"},{"key":"322_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1053\/j.gastro.2013.08.049","volume":"145","author":"T Ogino","year":"2013","unstructured":"Ogino T, Nishimura J, Barman S, Kayama H, Uematsu S, Okuzaki D, et al. Increased Th17-Inducing Activity of CD14+ CD163low Myeloid Cells in Intestinal Lamina Propria of Patients With Crohn\u2019s Disease. Gastroenterology. 2013;145:1380\u20131391.e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"322_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","volume":"68","author":"Sebastian Zeissig","year":"2018","unstructured":"Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68:25\u201339.","journal-title":"Gut"},{"issue":"4","key":"322_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","volume":"68","author":"Renaud Gaujoux","year":"2018","unstructured":"Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD. Gut. 2019;68:604\u201314.","journal-title":"Gut"},{"key":"322_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"KM de Lange","year":"2017","unstructured":"de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49:256\u201361.","journal-title":"Nat Genet"},{"key":"322_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12192","volume":"260","author":"CC Bain","year":"2014","unstructured":"Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. Immunol Rev. 2014;260:102\u201317.","journal-title":"Immunol Rev"},{"key":"322_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MIB.0b013e3182a69dca","volume":"20","author":"EC Steinbach","year":"2014","unstructured":"Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis. 2014;20:166\u201375.","journal-title":"Inflamm Bowel Dis"},{"key":"322_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/mi.2014.53","volume":"8","author":"Y Nakanishi","year":"2015","unstructured":"Nakanishi Y, Sato T, Ohteki T. Commensal gram-positive bacteria initiates colitis by inducing monocyte\/macrophage mobilization. Mucosal Immunol. 2015;8:152\u201360.","journal-title":"Mucosal Immunol"},{"key":"322_CR22","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1038\/ncomms8802","volume":"6","author":"K Asano","year":"2015","unstructured":"Asano K, Takahashi N, Ushiki M, Monya M, Aihara F, Kuboki E, et al. Intestinal CD169+ macrophages initiate mucosal inflammation by secreting CCL8 that recruits inflammatory monocytes. Nat Commun. 2015;6:7802.","journal-title":"Nat Commun"},{"key":"322_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/mi.2016.96","volume":"10","author":"K Arimura","year":"2017","unstructured":"Arimura K, Takagi H, Uto T, Fukaya T, Nakamura T, Choijookhuu N, et al. Crucial role of plasmacytoid dendritic cells in the development of acute colitis through the regulation of intestinal inflammation. Mucosal Immunol. 2017;10:957\u201370.","journal-title":"Mucosal Immunol"},{"key":"322_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coi.2016.06.006","volume":"41","author":"AM Newman","year":"2016","unstructured":"Newman AM, Alizadeh AA. High-throughput genomic profiling of tumor-infiltrating leukocytes. Curr Opin Immunol. 2016;41:77\u201384.","journal-title":"Curr Opin Immunol"},{"key":"322_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220.","journal-title":"Genome Biol"},{"key":"322_CR26","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"322_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"322_CR28","doi-asserted-by":"publisher","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","volume":"356","author":"A-C Villani","year":"2017","unstructured":"Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356:eaah4573.","journal-title":"Science"},{"key":"322_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1756283X13479826","volume":"6","author":"GR Lichtenstein","year":"2013","unstructured":"Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Ther Adv Gastroenterol. 2013;6:269\u201393.","journal-title":"Ther Adv Gastroenterol"},{"key":"322_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","volume":"32","author":"JW Griffith","year":"2014","unstructured":"Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659\u2013702.","journal-title":"Annu Rev Immunol"},{"key":"322_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cell.2018.08.067","volume":"175","author":"J Kinchen","year":"2018","unstructured":"Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, et al. Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease. Cell. 2018;175:372\u2013386.e17.","journal-title":"Cell"},{"key":"322_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/mi.2015.64","volume":"9","author":"ARBM Muzaki","year":"2016","unstructured":"Muzaki ARBM, Tetlak P, Sheng J, Loh SC, Setiagani YA, Poidinger M, et al. Intestinal CD103+CD11b\u2212 dendritic cells restrain colitis via IFN-\u03b3-induced anti-inflammatory response in epithelial cells. Mucosal Immunol. 2016;9:336\u201351.","journal-title":"Mucosal Immunol"},{"key":"322_CR33","doi-asserted-by":"publisher","unstructured":"Sawai CM, Serpas L, Neto AG, Jang G, Rashidfarrokhi A, Kolbeck R, et al. Plasmacytoid dendritic cells are largely dispensable for the pathogenesis of experimental inflammatory bowel disease. Front Immunol. 2018;9. https:\/\/doi.org\/10.3389\/fimmu.2018.02475.","DOI":"10.3389\/fimmu.2018.02475"},{"key":"322_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.chom.2014.03.006","volume":"15","author":"S Dasgupta","year":"2014","unstructured":"Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker H-C, Kasper DL. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe. 2014;15:413\u201323.","journal-title":"Cell Host Microbe"},{"key":"322_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12859-016-1012-y","volume":"17","author":"H Liu","year":"2016","unstructured":"Liu H, Liu J, Toups M, Soos T, Arendt C. Gene signature-based mapping of immunological systems and diseases. BMC Bioinformatics. 2016;17:171.","journal-title":"BMC Bioinformatics"},{"key":"322_CR36","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41385-018-0030-7","volume":"11","author":"D Bernardo","year":"2018","unstructured":"Bernardo D, Marin AC, Fern\u00e1ndez-Tom\u00e9 S, Montalban-Arques A, Carrasco A, Trist\u00e1n E, et al. Human intestinal pro-inflammatory CD11c high CCR2 + CX3CR1 + macrophages, but not their tolerogenic CD11c \u2212 CCR2 \u2212 CX3CR1 \u2212 counterparts, are expanded in inflammatory bowel disease. Mucosal Immunol. 2018;11:1114.","journal-title":"Mucosal Immunol"},{"key":"322_CR37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/mi.2016.94","volume":"10","author":"TM Fenton","year":"2017","unstructured":"Fenton TM, Kelly A, Shuttleworth EE, Smedley C, Atakilit A, Powrie F, et al. Inflammatory cues enhance TGF\u03b2 activation by distinct subsets of human intestinal dendritic cells via integrin \u03b1v\u03b28. Mucosal Immunol. 2017;10:624\u201334.","journal-title":"Mucosal Immunol"},{"key":"322_CR38","doi-asserted-by":"publisher","first-page":"e0130750","DOI":"10.1371\/journal.pone.0130750","volume":"10","author":"UA Wenzel","year":"2015","unstructured":"Wenzel UA, Jonstrand C, Hansson GC, Wick MJ. CD103+CD11b+ dendritic cells induce Th17 T cells in Muc2-deficient mice with extensively spread colitis. PLoS One. 2015;10:e0130750.","journal-title":"PLoS One"},{"key":"322_CR39","doi-asserted-by":"publisher","first-page":"e100217","DOI":"10.1371\/journal.pone.0100217","volume":"9","author":"UA Wenzel","year":"2014","unstructured":"Wenzel UA, Magnusson MK, Rydstr\u00f6m A, Jonstrand C, Hengst J, Johansson ME, et al. Spontaneous colitis in Muc2-deficient mice reflects clinical and cellular features of active ulcerative colitis. PLoS One. 2014;9:e100217.","journal-title":"PLoS One"},{"key":"322_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2249.2011.04439.x","volume":"166","author":"DC Baumgart","year":"2011","unstructured":"Baumgart DC, Metzke D, Guckelberger O, Pascher A, Gr\u00f6tzinger C, Przesdzing I, et al. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn\u2019s disease and ulcerative colitis. Clin Exp Immunol. 2011;166:46\u201354.","journal-title":"Clin Exp Immunol"},{"key":"322_CR41","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","volume":"178","author":"CS Smillie","year":"2019","unstructured":"Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, et al. Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell. 2019;178:714\u2013730.e22.","journal-title":"Cell"},{"key":"322_CR42","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","volume":"178","author":"JC Martin","year":"2019","unstructured":"Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, et al. Single-Cell Analysis of Crohn\u2019s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell. 2019;178:1493\u20131508.e20.","journal-title":"Cell"},{"key":"322_CR43","doi-asserted-by":"publisher","unstructured":"Obregon C, Kumar R, Pascual MA, Vassalli G, Golshayan D. Update on dendritic cell-induced immunological and clinical tolerance. Front Immunol. 2017;8. https:\/\/doi.org\/10.3389\/fimmu.2017.01514.","DOI":"10.3389\/fimmu.2017.01514"},{"key":"322_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"SH Lee","year":"2018","unstructured":"Lee SH, eun KJ, Cho M-L. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26\u201342.","journal-title":"Intest Res"},{"key":"322_CR45","doi-asserted-by":"publisher","unstructured":"Geremia A, Arancibia-C\u00e1rcamo CV. Innate lymphoid cells in intestinal inflammation. Front Immunol. 2017;8. https:\/\/doi.org\/10.3389\/fimmu.2017.01296.","DOI":"10.3389\/fimmu.2017.01296"},{"key":"322_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/cmi.2016.55","volume":"14","author":"D Wu","year":"2017","unstructured":"Wu D, Wu P, Qiu F, Wei Q, Huang J. Human \u03b3\u03b4T-cell subsets and their involvement in tumor immunity. Cell Mol Immunol. 2017;14:245\u201353.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"322_CR47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/ecco-jcc\/jjz015","volume":"13","author":"Elena Lo Presti","year":"2019","unstructured":"Lo Presti E, Di Mitri R, Mocciaro F, Di Stefano AB, Scibetta N, Unti E, et al. Characterization of \u03b3\u03b4 T cells in intestinal mucosa from patients with early onset or long standing inflammatory bowel disease and their correlation with clinical status. J Crohns Colitis. 2019;13:873\u201383. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz015.","journal-title":"Journal of Crohn's and Colitis"},{"key":"322_CR48","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/gut.2006.103523","volume":"56","author":"IL Huibregtse","year":"2007","unstructured":"Huibregtse IL, van Lent AU, van Deventer SJH. Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut. 2007;56:584\u201392.","journal-title":"Gut"},{"key":"322_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/MOG.0b013e328311f26e","volume":"24","author":"EK Boden","year":"2008","unstructured":"Boden EK, Snapper SB. Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol. 2008;24:733.","journal-title":"Curr Opin Gastroenterol"},{"key":"322_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","volume":"18","author":"E Papalexi","year":"2018","unstructured":"Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18:35\u201345.","journal-title":"Nat Rev Immunol"},{"key":"322_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","volume":"4","author":"E Martini","year":"2017","unstructured":"Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4:33\u201346.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"322_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411\u201320.","journal-title":"Nat Biotechnol"},{"key":"322_CR53","doi-asserted-by":"publisher","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","volume":"4","author":"I Arijs","year":"2009","unstructured":"Arijs I, Hertogh GD, Lemaire K, Quintens R, Lommel LV, Steen KV, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009;4:e7984.","journal-title":"PLoS One"},{"key":"322_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","volume":"67","author":"I Arijs","year":"2018","unstructured":"Arijs I, Hertogh GD, Lemmens B, Lommel LV, de Bruyn M, Vanhove W, et al. Effect of vedolizumab (anti-\u03b14\u03b27-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67:43\u201352.","journal-title":"Gut"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-019-0322-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12865-019-0322-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-019-0322-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:14:20Z","timestamp":1605053660000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-019-0322-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1186\/s12865-019-0322-z","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"22 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were ethically performed according to our institutional guidelines. We are an AAALAC accredited organization using The Guide for the Care and Use of Laboratory Animals (Guide) as the primary standard for our animal care and use program. We are also a registered research facility with the California Department of Health Services and hold a Certificate of Approval to Keep and Use Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Takeda Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}